Timing note: Biogen’s Q2 report is scheduled for Wednesday, July 29, 2026, before the market opens, with the call at 8:30 a.m. ET. As of the current date, July 29 is today, not tomorrow. (investors.biogen.com)
This report is less about whether Biogen beats a noisy quarterly EPS estimate and more about whether management can establish a credible post-Apellis earnings and growth baseline.
The three most important issues are:
A clean revenue beat would help, but investors are likely to place substantially more weight on guidance quality, Apellis integration and management’s answers around diranersen.
Publicly available consensus feeds are not particularly consistent. They point to approximately $2.4 billion to $2.5 billion of revenue, while published adjusted EPS estimates range from roughly $2.35 to $2.98. The variation likely reflects, at least in part, different treatments of Biogen’s acquired R&D expenses. (benzinga.com)
Biogen has already disclosed that Q2 results will include:
This makes the headline EPS comparison unusually difficult. Investors should separate:
At Q1, Biogen’s guidance—excluding Apellis—called for 2026 non-GAAP EPS of $14.25-$15.25 and a mid-single-digit decline in revenue. Management explicitly said it would issue guidance including Apellis with Q2 results. (investors.biogen.com)
Biogen completed its approximately $5.3 billion acquisition of Apellis on May 14, meaning Q2 should contain roughly seven weeks of Apellis operations. The acquisition added SYFOVRE for geographic atrophy and EMPAVELI for complement-driven diseases. Biogen expects the transaction to be accretive to non-GAAP EPS in 2027. (investors.biogen.com)
Apellis reported Q1 2026 product revenue of:
| Product | Q1 2026 revenue | YoY growth |
|---|---|---|
| SYFOVRE | $150.7M | 16% |
| EMPAVELI | $41.3M | 109% |
| Total product revenue | $192.0M | 28% |
Apellis also reported $76.3 million of licensing and other revenue, but $55 million came from regulatory and collaboration payments. That portion should not be treated as recurring product revenue. (sec.gov)
At the Q1 product run rate, approximately seven weeks of ownership would equate to roughly $100 million of product revenue consolidated into Biogen’s Q2 results. That is only an illustrative calculation; purchase accounting, transaction timing, inventory and normal commercial variability could produce a materially different number.
Biogen borrowed $2 billion to help fund the transaction, split between a $1 billion facility due in May 2027 and another $1 billion due in May 2028. The balance sheet and repayment plan therefore matter more than they did before the acquisition. (sec.gov)
Best outcome: management shows that Apellis adds durable mid-teens-or-better product growth without requiring enough incremental spending to delay 2027 accretion.
Key risk: SYFOVRE growth proves more promotion-sensitive than expected while higher commercial costs and interest expense pressure near-term EPS.
LEQEMBI generated $168 million of global end-market sales in Q1, up 74% year over year. Biogen recognized $59.5 million of Alzheimer’s collaboration revenue.
The most important questions are:
The FDA approved LEQEMBI IQLIK for at-home initiation dosing on July 13, with the U.S. launch planned for late August. Because approval came after quarter-end, it will not materially affect Q2 sales. Its significance is in the forward outlook: initiation and maintenance can now both be delivered through a weekly autoinjector rather than requiring patients to begin with IV infusions. (investors.biogen.com)
A strong report would include clear launch metrics and evidence that subcutaneous initiation can expand the addressable market—not simply shift existing patients from IV to subcutaneous treatment.
SKYCLARYS produced $151 million in Q1, up 22% year over year. The underlying story was stronger outside the U.S., where revenue exceeded U.S. revenue for the first time.
The central question is whether ex-U.S. reimbursement decisions are converting patients from early-access programs into paying commercial patients. This can make quarterly revenue lumpy, but it is also the product’s main medium-term growth engine.
A result above Q1’s $151 million level, supported by demand rather than inventory, would be constructive.
Q1 SPINRAZA revenue declined 12% to $374 million, partly because of ex-U.S. shipment timing. The high-dose regimen has since launched in the U.S., Europe and Japan.
Management previously said that shortly after the U.S. launch, start forms covering roughly 20% of the existing patient base had already been submitted, with a similar conversion rate emerging in Germany. Investors should look for:
Shipment timing will remain a source of quarterly volatility, so patient and demand metrics may be more informative than reported revenue.
Q1 VUMERITY revenue was $179 million, up 29%, but benefited from U.S. inventory dynamics. TYSABRI also benefited from favorable gross-to-net adjustments and inventory timing.
The risk for Q2 is reversal of those favorable items. Investors should avoid interpreting another resilient MS quarter as sustainable unless management can demonstrate stable underlying prescriptions and market share.
ZURZUVAE generated $55 million in Q1, up 100% year over year, while QALSODY produced $33 million, up 110%.
Both remain smaller contributors, but continued demand growth would support Biogen’s argument that its newer portfolio can progressively offset legacy MS erosion.
Diranersen, formerly BIIB080, has become a potentially important valuation asset following the Phase 2 CELIA results.
At the lowest tested regimen—60 mg administered intrathecally every six months—the study showed:
However, CELIA did not meet its primary endpoint, which tested for a dose-response relationship. Higher doses did not generate greater clinical benefit, and no separation from placebo was seen on the ADCS-ADL-MCI functional endpoint at 18 months. (biogen.gcs-web.com)
That leaves several critical questions for the call:
A credible, capital-disciplined registrational plan could add confidence. A vague or unusually large development program could raise concerns that the encouraging low-dose results may be difficult to reproduce.
The cleanest way to judge the report will be to compare new guidance with the old ex-Apellis baseline.
Because company-defined non-GAAP EPS includes acquired-R&D charges, a lower headline EPS range may be largely mechanical. Investors should reconstruct guidance before those charges to determine whether the operating outlook has actually weakened.
The most important number in this report probably will not be Q2 EPS. It will be the implied earnings power of the combined Biogen-Apellis business after normalizing acquired-R&D charges, purchase accounting and financing costs.
For the stock to respond positively, management needs to show that:
A modest quarterly beat without convincing combined-company guidance would be less meaningful than an in-line quarter accompanied by strong product trends, clean guidance and a credible deleveraging plan.